NFKB1 and Burkitt lymphoma: Importantly, switching to an LMP1-positive Latency II or III infection could offer greater protection; however such cells would cease to proliferate because, as many in vitro studies have shown [147,148], LMP1-driven signalling is incompatible with the c-MYC-driven (NF-κB-silent, non-inflammatory) gene expression programme that is crucial to BL cell growth.